An experimental weight-loss drug, retatrutide, has shown promising results in reducing knee pain and body weight among people with obesity or overweight who also have painful knee osteoarthritis. The findings come from two Phase 3 clinical trials, TRIUMPH-4 and TRIUMPH-1-OA, involving 1,019 participants combined. The studies evaluated the effects of once-weekly retatrutide injections against a placebo. In TRIUMPH-4, participants receiving the 12 mg dose recorded an average body-weight reduction of 23.7% after 68 weeks, compared with 4.6% in the placebo group. Researchers also reported improvements in knee pain. In the second trial, pain scores improved across the retatrutide dose groups compared with placebo. New England Journal of Medicine A pooled analysis reported that around two-thirds of participants taking retatrutide experienced at least a 50% reduction in knee pain, compared with 38% of those receiving placebo. Researchers believe weight reduction may ease pressure on the knee joints, making everyday activities such as walking and climbing stairs easier. Retatrutide works by activating three hormone receptors: GIP, GLP-1 and glucagon. It is being developed by Eli Lilly as a once-weekly injectable medicine. However, the findings do not mean the drug is ready for routine treatment. Retatrutide remains investigational and has not received regulatory approval. Gastrointestinal problems were among the most common adverse events, while serious adverse events were more frequent in the retatrutide groups than in the placebo groups. The trials were funded by Eli Lilly, and some study authors were company employees. Further regulatory review will be needed before the medicine can become an approved treatment.
Retatrutide Cuts Knee Pain and Body Weight in Osteoarthritis Trials
An analysis of two Phase 3 trials found that experimental drug retatrutide helped reduce body weight and knee pain in people with obesity or overweight and painful knee osteoarthritis. Around two-thirds of participants receiving the highest dose reported at least a 50% reduction in knee pain.


0 comments
No comments yet. Yours would be the first.